-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
WAG Stock – Walgreen Is Strong Enough to Wiggle Higher
The mixed market is punishing some sectors and rewarding others. But Walgreen could excel on its own given the relative strength of WAG stock.
Marijuana Stocks Could be Scams, Warns SEC Watchdogs
The marijuana industry could be very big business one day, but buying marijuana stocks now only raises the risk of getting ripped off.
Dow Theory Buy Signal Confirmed
The industrials broke to a new closing high, putting the pressure on the bears.
AZN, PFE: Pfizer Confirms Interest in Buying AstraZeneca
Pfizer says it has approached AstraZeneca about a possible $100 billion merger deal, sending AZN stock surging in Monday trading.
2 Clear Signs That Biotechs and Pharmaceuticals Have Peaked
Pharmaceuticals and biotechs have been too hot for their own good, fueled by increasingly iffy M&A and an oddly high level of IPO activity.
CYTK: Cytokinetics Stock in Ugly Free Fall on ALS Drug Fail
Cytokinetics stock plunged 60% after CYTK revealed that its amyotrophic lateral sclerosis drug hadn't met the primary goal of a mid-stage clinical trial.
ABBV: AbbVie Beats Street on Soaring Humira Sales
Pharmaceutical-maker AbbVie posted first-quarter sales that beat estimates on surging sales of its Humira drug, sending ABBV stock higher.
Grass Pollen Allergy? New Grastek Pill From Merck Hits Shelves Soon
Merck says the U.S. Food and Drug Administration has approve the release of its Grastek grass pollen allergy drug, which will launch later this month.
PHOT Suspended by SEC – Sell Your Marijuana Stocks (While You Still Can)
The SEC has halted trading in Growlife (PHOT) over potential securities fraud. Which of the well-known marijuana stocks will be next?
3 Biotech Stocks That Could Keep Bombing
After years of unchecked rallying in biotech stocks, a correction is finally upon us. And as bad as things have been, the mean-reversion move could go even lower.
Healthcare Stocks Are Tempting, But Don’t Buy Just Yet
Healthcare stocks have dipped lower for the past month, which might seem like a buying opportunity. But long-term investors should wait for a better bargain.
Pharmaceuticals Deals: QCOR Gets a Big Premium, Roche Goes Shopping
Monday's big pharmaceuticals deals included Mallinckrodt buying Questcor for $5.6B -- a 27% premium to QCOR stock -- and Roche picking up Ranbaxy.
MNKD Stock, Take Two: Volatility or Not, You Have to Like Afrezza
Unfortunately, a bet on MNKD stock right now isn't a bet on the potential of Afrezza. But sooner or later, these facts will be reflected in MannKind shares.
MNKD: Buy the Rumor, Sell the News
MannKind has much to be excited about today with Afrezza, but investors need to recognize a troubling pattern that could upend MNKD stock.
4 Medical Marijuana Stocks to Dump Now
'Medical' marijuana stocks are all the rage, but most are barely real companies -- and have nothing to do with the legalization of marijuana, anyway.
4 Ways Obamacare Will Affect Stocks
Obamacare is here to stay. That's good for some stocks, and horrible for others. Here's a look at the winners and losers.
Ready, Aim, Bargain Hunt
Those with a good risk tolerance should use the current weakness to buy high-quality, oversold stocks.
VIDEO: Biotechs Fall, Momentum Stocks Break Down and More
Charles Sizemore sits down to talk biotech and momentum stocks with Fox Business' Charles Payne.
New Biotech Breakthrough: Buy Intermune Stock
A raft of good news has powered Intermune, and I believe the good news will continue, and Intermune stock is a buy
